Aug. 21, 2007--Sirtris Pharmaceuticals (NASDAQ: SIRT), a biopharmaceutical company announced the initiation of a Phase 2a clinical trial to evaluate its SRT501 product candidate in patients with Type 2 Diabetes whose glucose levels are not adequately controlled by their metformin treatment... Sitris' Press ReleaseBlog Archive
-
▼
2007
(88)
-
▼
August
(15)
- Needle-Free Drug Delivery Technology for Diabetes ...
- BodyTel Scientific to Exhibit the GlucoTel System ...
- Pfizer and Bristol-Myers Squibb Worldwide Collabor...
- Teijin and Chugai, agreement to co-develop Ipsen's...
- Cannasat Therapeutics, Commence Phase 1 Study of C...
- AtheroGenics , Phase III clinical trial of AGI-106...
- Blood Glucose Meter, Medtronic and LifeScan Annou...
- Sirtris Pharmaceuticals, SRT501 product candidate ...
- Blood Glucose Meter, Medtronic and Bayer Diabetes ...
- Novo Nordisk, Liraglutide improves glucose control
- Diabetic Neuropathic Pain, UCB's subsidiary SCHWAR...
- Oramed oral insulin gel capsule
- CombinatoRx CRx-401 for Type 2 Diabetes
- Avigen, Neuropathic Pain : Clinical Development fo...
- a news diabetes blog
-
▼
August
(15)
Wednesday, August 22, 2007
Sirtris Pharmaceuticals, SRT501 product candidate in patients with Type 2 Diabetes
Aug. 21, 2007--Sirtris Pharmaceuticals (NASDAQ: SIRT), a biopharmaceutical company announced the initiation of a Phase 2a clinical trial to evaluate its SRT501 product candidate in patients with Type 2 Diabetes whose glucose levels are not adequately controlled by their metformin treatment... Sitris' Press Release
